Farmak International Delivers First Shipment of Injectable Medicines to China

Last week, Farmak International — a member of the Farmak Group and responsible for expanding the company’s presence in international markets — successfully completed its first shipment of injectable pharmaceuticals to China. Specifically, the delivery included a diagnostic contrast agent used in magnetic resonance imaging (MRI).

This shipment was made as part of China’s national Volume-Based Procurement (VBP) program for centralized government purchases of large volumes of medicines. Farmak International emerged as the only foreign manufacturer to win the tender, underscoring the high competitiveness and quality of the company’s sterile injectables portfolio.

Notably, the company received its first marketing authorization in China only at the end of 2024. Now, less than six months later, the first delivery has already been made.

The Farmak Group is a global pharmaceutical enterprise founded in Ukraine in 1925, with manufacturing facilities in two European countries (Ukraine and Spain), and 11 subsidiaries and international offices across Poland, the Czech Republic, Slovakia, the United Kingdom, the UAE, Vietnam, Switzerland, Kazakhstan, Uzbekistan, Kyrgyzstan, and Moldova. Products of the Farmak Group are exported to over 60 countries worldwide, including 15 EU member states, and are manufactured in accordance with the high European GMP (Good Manufacturing Practice) standards.